Starting to invest for the first time can feel intimidating, especially when there are thousands of options to choose from. But by using a Stocks and Shares ISA and focusing on a handful of stable, high‑quality FTSE shares, beginners can build a solid foundation that does a lot of the heavy lifting for them.
Here are two proven FTSE 100 stalwarts that many institutional investors already see as core holdings, not speculative side bets.
Why AstraZeneca could be a great starter stock
AstraZeneca‘s (LSE:AZN) one of the world’s biggest drugmakers. It develops medicines across oncology, cardiovascular, respiratory, and rare diseases, and that broad mix helps reduce dependence on any one product. That’s a handy advantage in generating diversified cash flows.
Its latest results showed momentum remained solid, with May guidance pointing to mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share.
The bull case is straightforward:
- Demand for innovative medicines continues to strengthen alongside an ageing population.
- The development pipeline for new treatments and medicines remains deep.
- The company has the scale to keep investing heavily in research.
However, like all investments, even a firm as big as AstraZeneca has its weak spots.
Drug development’s notoriously expensive, competition never sleeps, and setbacks in clinical trials or regulatory decisions can hit sentiment fast. The latter could prove particularly problematic in the coming years given several of AstraZeneca’s blockbuster drugs will be losing their patent protection – a key risk for investors to monitor.
A steadier consumer giant
The second pick to consider is Unilever (LSE:ULVR), the global consumer goods giant with brands across food, home care, beauty, and personal care.
For beginners, this kind of everyday-demand business can be a great foundation. After all, regardless of what the economy’s doing, people need to keep buying shampoo, soap, and other household staples. And with management unveiling plans to merge its food business with US-based peer McCormick, the company’s aiming to evolve and reshape its product portfolio in line with the times.
Yet even with this merger, Unilever still owns powerful brands, produces strong cash flow, and offers the sort of defensive quality that many first-time investors want in an ISA. The food deal could also sharpen the company’s focus by simplifying and creating a more streamlined consumer business over time.
However, just like AstraZeneca, there are some important risks to highlight.
The McCormick merger announcement has been quite controversial, with some investors questioning the logic and structure of the actual deal. And even if it goes ahead, there are all the risk factors associated with a merger of this scale, including integration, execution, and even regulation.
The market’s initial reaction was pretty chilly. So while the opportunity’s real, so is the uncertainty.
The bottom line
For beginners, these are the kind of FTSE shares that can help a new ISA feel less like a gamble and more like a long-term plan.
Neither’s a guaranteed winner, but both hold traits that set them up for long-term success. AstraZeneca brings medical innovation and earnings power, while Unilever offers defensive brands, cash generation, and a possible strategic reset.
Taken together, they look like a solid starting pair for investors who want quality first and excitement second. That’s why I think they both deserve a closer look.
Should you invest £5,000 in AstraZeneca Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca Plc made the list?
Zaven Boyrazian does not hold any positions in the companies mentioned.
